RAVI GARIGIPATI Synthetic Chemistry and CMC

EDUCATION: PhD-Synthetic Organic Chemistry, Penn State University with Prof. Steve Weinreb.

EXPERIENCE: 1988-1997 SmithKline and Beecham, Medicinal Chemistry. 1997-2017 Pfizer Global R&D, Emerging Medicinal Sciences, Atherosclerosis Med. Chem., Process Chemistry and CMC Technical leadership.

EXPERTISE: Inflammation and Immunology, Atherosclerosis, Medicinal Chemistry, Medicinal Technologies, Outsourcing, CMC leadership and execution. Over 70 patents and publications.

BIO

Ravi has 35 years of wide-ranging R&D experience in the Pharma industry. His interest in organic chemistry started in high school and he earned his Ph.D. in synthetic organic chemistry with Steve Weinreb at Penn State. Ravi started his career at SmithKline Beecham working in Inflammation, Osteoporosis and Medicinal Technology areas. He has led Med. Chem teams in the design and advancement of molecules to nomination for clinical studies. His contributions led to two p38 inhibitors which entered clinical trials. After ten years at SmithKline he moved to Pfizer where he spent 20 years. He worked in Atherosclerosis, Inflammation and Technology areas. He led the efforts to identifying novel strategies for library generation. Ravi designed and optimized water soluble CETP inhibitors which went into human clinical trials. After ten years, Ravi moved to the development side. He established and nurtured a group for manufacture of GMP APIs and intermediates at external collaborators. He was a Pharm Sci Team Lead (PSTL or CMC technical lead) for eight years. Over that time, he led efforts for several agents from lead discovery stage to Ph I clinical trials. His efforts resulted in eight POCs/Ph III study starts. He has over 70 publications and patents.